MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-26-2026
Orgenesis Net Income 2011-2026 | ORGS
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Orgenesis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -48.2 M | -55.4 M | -14.9 M | -18.1 M | 1.11 M | -24.1 M | -18.3 M | -12.4 M | -9.19 M | -4.46 M | -5.5 M | -5.54 M | -5 M | -72.4 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 M | -55.4 M | -15.7 M |
Quarterly Net Income Orgenesis
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.12 M | -8.9 M | -9.76 M | - | -3.72 M | -25.5 M | -19.5 M | - | -1.36 M | -5.43 M | -4.01 M | - | -10.2 M | -2.66 M | -219 K | - | 2.43 M | 20.4 M | -70 M | - | 4.55 M | 5.2 M | 8.31 M | - | -5.07 M | -2.61 M | -2.74 M | - | -3.94 M | -2.49 M | -6.13 M | - | -2.64 M | -3.89 M | 225 K | - | -1.62 K | -1.1 K | -790 | - | -3.49 M | -1.8 M | -709 K | - | -937 K | -1.56 M | -1.33 M | - | -1.88 M | -875 K | -5 M | - | -72.4 K | -72.4 K | -72.4 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.4 M | -70 M | -4.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
265 M | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 229.25 | 0.44 % | $ 5 B |  Danmark |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
AbbVie
ABBV
|
1.82 B | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-3.08 M | $ 3.33 | -2.06 % | $ 99 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-59.5 M | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
-88.1 M | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 91.18 | 1.97 % | $ 27.2 B | Germany |
 |
Amgen
AMGN
|
7.71 B | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
-18.5 M | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-65.8 M | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aurinia Pharmaceuticals
AUPH
|
211 M | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.68 | 1.52 % | $ 16.8 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
115 M | - | - | $ 96.9 B | Britain |
 |
Burford Capital Limited
BUR
|
172 M | $ 4.14 | -2.59 % | $ 683 M | Britain |
 |
Avenue Therapeutics
ATXI
|
-2.91 M | - | -52.27 % | $ 4.45 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-158 M | $ 5.76 | 1.95 % | $ 469 M | USA |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-88.9 M | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Axcella Health
AXLA
|
-81.2 M | - | -16.42 % | $ 249 M | USA |
 |
Axon Enterprise
AXON
|
377 M | $ 412.81 | -2.54 % | $ 31.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
314 M | $ 318.85 | -3.01 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |